CoChat

Insulin priming effect on estradiol-induced breast cancer metabolism and growth

Open access
Wairagu, Peninah M, Phan, Ai NH, Kim, Min-Kyu, Han, Jeongwoo, Kim, Hyun-Won, Choi, Jong-Whan, Kim, Ki Woo, Cha, Seung-Kuy, Park, Kwang Hwa, Jeong, Yangsik · 2015 · Cancer Biology & Therapy
Cited by 37

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Diabetes is a risk factor for breast cancer development and is associated with poor prognosis for breast cancer patients. However, the molecular and biochemical mechanisms underlying the association between diabetes and breast cancer have not been fully elucidated. Here, we investigated estradiol response in MCF-7 breast cancer cells with or without chronic exposure to insulin. We found that insulin priming is necessary and specific for estradiol-induced cancer cell growth, and induces anaplerotic shunting of glucose into macromolecule biosynthesis in the estradiol treated cells. Treatment with ERK or Akt specific inhibitors, U0126 or LY294002, respectively, suppressed estradiol-induced growth. Interestingly, molecular analysis revealed that estradiol treatment markedly increases expression of cyclin A and B, and decreases p21 and p27 in the insulin-primed cells. In addition, estradiol treatment activated metabolic genes in pentose phosphate (PPP) and serine biosynthesis pathways in the insulin-primed cells while insulin priming decreased metabolic gene expression associated with glucose catabolism in the breast cancer cells. Finally, we found that anti-diabetic drug metformin and AMPK ligand AICAR, but not thiazolidinediones (TZDs), specifically suppress the estradiol-induced cellular growth in the insulin-primed cells. These findings suggest that estrogen receptor (ER) activation under chronic hyperinsulinemic condition increases breast cancer growth through the modulation of cell cycle and apoptotic factors and nutrient metabolism, and further provide a mechanistic evidence for the clinical benefit of metformin use for ER-positive breast cancer patients with diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/15384047.2015.1016660

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 37

Metadata

Authors
Wairagu, P. M., Phan, A. N., Kim, M.-K., Han, J., Kim, H.-W., Choi, J.-W., Kim, K. W., Cha, S.-K., Park, K. H., & Jeong, Y.
Venue
Cancer Biology & Therapy
Published
2015-02-20
Volume
16
Issue
3
Pages
484-492
ISSN
  • 1538-4047 (ISSN-L)
  • 1555-8576
OpenAlex
W1580610162
Cited by
37
References
6
FWCI
1.29
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin priming effect on estradiol-induced breast cancer metabolism and growth. https://app.cochat.ai/papers/10.1080/15384047.2015.1016660
The paper
Wairagu, P. M., Phan, A. N., Kim, M.-K., Han, J., Kim, H.-W., Choi, J.-W., Kim, K. W., Cha, S.-K., Park, K. H., & Jeong, Y. (2015). Insulin priming effect on estradiol-induced breast cancer metabolism and growth. Cancer Biology & Therapy. https://doi.org/10.1080/15384047.2015.1016660

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.